Preclinical inhibition of CD44 using monoclonal antibodies or gene silencing has reduced tumor cell proliferation, MDSC recruitment, and fibrotic signaling in hepatocellular carcinoma [12]. This evidence concerns the gene CD44 and hepatocellular carcinoma.